venetoclax + obinutuzumab + cyclophosphamide + doxorubicin + vincristine + prednisone

This drug is a **multi-agent combination regimen** of six pharmaceuticals, comprising: - **Venetoclax**, an oral small-molecule inhibitor of the BCL-2 anti-apoptotic protein, promoting apoptosis in malignant B-cells. - **Obinutuzumab**, a type II glycoengineered anti-CD20 monoclonal antibody that induces direct cell death and antibody-dependent cell-mediated cytotoxicity. - **Cyclophosphamide**, an alkylating agent that crosslinks DNA, leading to cell death, used broadly as chemotherapy. - **Doxorubicin**, an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, impeding DNA replication and transcription. - **Vincristine**, a vinca alkaloid that interrupts microtubule formation, stopping cell division. - **Prednisone**, a synthetic glucocorticoid corticosteroid with immunosuppressive and anti-inflammatory effects. This combination is not a standard named regimen but represents the **addition of a modern targeted (venetoclax and obinutuzumab) doublet to the classic CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) backbone**. The combination could be considered for the treatment of **B-cell malignancies**, specifically chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), but there is **no direct regulatory approval or common clinical use for this exact six-drug regimen**. Each drug in the regimen targets a **different pathway in malignant cell survival or proliferation**, resulting in potentially synergistic anti-tumor effects.